LPCN 1148, an oral prodrug of bioidentical testosterone, was recently studied in a proof-of-concept (POC) Phase 2 study in patients with decompensated cirrhosis. Treatment with LPCN 1148 in the ...

This article explores compensated cirrhosis in more detail, including its causes, diagnosis, and treatment. It also answers some common questions about the condition. Healthcare professionals ...

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment ...

The global cirrhosis management market is projected to grow from US$ 725 million in 2023 to US$ 1,052.3 million by 2033, with ...

Biomarker staging of liver fibrosis in hepatitis C was cost effective, but so was initiating treatment without testing.

Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosisalfapump® is ...

Trans- versus cisgender adults have an increased prevalence of cirrhosis but similar five-year survival, according t ...

Regular coffee consumption (2-3 cups/day) protects against liver cirrhosis, reduces fibrosis, prevents liver cancer, and ...

The following is a summary of “Evaluating the GALAD Score for Detection of Hepatocellular Carcinoma in Patients With ...

US FDA grants fast track designation to Lipocine’s LPCN 1148 as a treatment for sarcopenia in patients with decompensated cirrhosis: Salt Lake City Thursday, December 19, 2024, ...

Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis KOL Webcast on January 8, 2025 – 3pm CET, 9am ET The Company ...